Aclaris Therapeutics Reports Fourth Quarter and Full Year 2015 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Aclaris Therapeutics (ACRS) Reports Q4 Loss of $0.28/Share
March 23, 2016 4:04 PM EDTAclaris Therapeutics (NASDAQ: ACRS) reported Q4 EPS of ($0.28), versus ($1.76) reported last year.
For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.
... More